Although TRAIL can stimulate the expression of prometastatic molecules like CXCL5/ENA-78 and IL-6 in prostate cancer cells, this effect can be countered using an AKT inhibitor combined with TRAIL (107). The gene discussed is CXCL5; the disease is prostate carcinoma.